Loading clinical trials...
Loading clinical trials...
A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy Participants
Conditions
Interventions
APB-R3
Placebo
Locations
1
Australia
CMAX Clinical Research
Adelaide, South Australia, Australia
Start Date
March 8, 2023
Primary Completion Date
December 19, 2023
Completion Date
December 19, 2023
Last Updated
January 8, 2024
Lead Sponsor
Syneos Health
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions